Resolvin D1-mediated cellular crosstalk protects against MASH

MASH is a growing healthcare burden worldwide. However, current treatments for MASH and its sequelae remain limited. Recent studies highlighted the therapeutic benefit of specialized pro-resolving mediators (SPMs), including RvD1, in liver diseases. However, the mechanisms underlying these beneficial effects are not well understood. Based on a series of co-culture primary cell experiments and unbiased transcriptomic analyses, we show that RvD1-mediated cellular crosstalk among hepatocytes and nonparenchymal cells protects against MASH progression. Our study provides a new mechanistic insight into the role of RvD1 in MASH and highlights its therapeutic potential to treat this condition.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2025-05-14
DOI
https://doi.org/10.1016/j.jhepr.2025.101454
Citations
3
Primary Topic
Advanced Glycation End Products research
Type
article
Field-Weighted Citation Impact
3.96

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Resolvin D1-mediated cellular crosstalk protects against MASH

Amaia Navarro‐Corcuera, Jerry E. Chipuk, Neha Gupta, Bruno Cogliati et al.
3 citations
JHEP Reports
Advanced Glycation End Products research
3.96
article

Resolvin D1-mediated cellular crosstalk protects against MASH

Amaia Navarro‐Corcuera, Jerry E. Chipuk, Neha Gupta, Bruno Cogliati, Oren Rom, Brian E. Sansbury, Haley Asplund, Yiwei Zhu, Scott L. Friedman, Fanglin Ma, Xin Huang, Bishuang Cai
article en
3 citations

Abstract

MASH is a growing healthcare burden worldwide. However, current treatments for MASH and its sequelae remain limited. Recent studies highlighted the therapeutic benefit of specialized pro-resolving mediators (SPMs), including RvD1, in liver diseases. However, the mechanisms underlying these beneficial effects are not well understood. Based on a series of co-culture primary cell experiments and unbiased transcriptomic analyses, we show that RvD1-mediated cellular crosstalk among hepatocytes and nonparenchymal cells protects against MASH progression. Our study provides a new mechanistic insight into the role of RvD1 in MASH and highlights its therapeutic potential to treat this condition.

JHEP ReportsVol. 7(8)
Louisiana State University (US), University of Louisville (US), Columbia University Irving Medical Center (US), Icahn School of Medicine at Mount Sinai (US)
Irma T. Hirschl Trust, Monique Weill-Caulier Trust, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Openalex Percentile: Top 7%
Advanced Glycation End Products research
3.96
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.